![]() |
|
|
Vol. 29, Issue 10, 1307-1315, October 2001
College of Pharmacy and Upjohn Center for Clinical Pharmacology,
University of Michigan, Ann Arbor, Michigan (C.S., H.S., D.E.S.); and
Department of Physiology and Biophysics, Case Western Reserve
University, Cleveland, Ohio (U.H.)
The objective of this study was to delineate the transepithelial
transport mechanisms of fosinopril in cultured cell lines expressing
the intestinal and renal peptide transporters. Lineweaver-Burk, Dixon,
and dose-response analyses revealed that GlySar uptake was
competitively inhibited by fosinopril in both Caco-2
(Ki, 35.5 µM) and SKPT cells
(Ki, 29.6 µM). Intracellular accumulations of fosinopril were 3 to 4 times higher from apical versus basolateral surfaces of the membrane, as was the apical-to-basal flux of the drug.
The apical peptide transporter had a significantly greater affinity for
fosinopril than did the basolateral peptide transporter in Caco-2 cells
(Km, 154 versus 458 µM, respectively;
p < 0.001) and SKPT cells
(Km, 22 versus 104 µM, respectively;
p < 0.001). Moreover, fosinopril uptake by the
basolateral peptide transporter was less sensitive to changes in medium
pH than the apical peptide transporter in both cell lines. Although
Caco-2 cells are known to express PEPT1 protein (and not PEPT2), our
immunoblot analyses provide definitive evidence that SKPT cells express
PEPT2 protein (and not PEPT1). Taken as a whole, our findings
demonstrate that fosinopril is transported intact by PEPT2 and PEPT1,
with high-affinity and by a proton-coupled, saturable process. Our
results also suggest that distinct peptide transporters exist at the
basolateral and apical membranes and that they play an important role
in modulating the intestinal absorption and renal reabsorption of
peptides and peptide-like drugs.
This article has been cited by other articles:
![]() |
A. S. Heimann, I. Gomes, C. S. Dale, R. L. Pagano, A. Gupta, L. L. de Souza, A. D. Luchessi, L. M. Castro, R. Giorgi, V. Rioli, et al. Hemopressin is an inverse agonist of CB1 cannabinoid receptors PNAS, December 18, 2007; 104(51): 20588 - 20593. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Ocheltree, H. Shen, Y. Hu, R. F. Keep, and D. E. Smith Role and Relevance of Peptide Transporter 2 (PEPT2) in the Kidney and Choroid Plexus: In Vivo Studies with Glycylsarcosine in Wild-Type and PEPT2 Knockout Mice J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 240 - 247. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Shu, H. Shen, N. S. Teuscher, P. J. Lorenzi, R. F. Keep, and D. E. Smith Role of PEPT2 in Peptide/Mimetic Trafficking at the Blood-Cerebrospinal Fluid Barrier: Studies in Rat Choroid Plexus Epithelial Cells in Primary Culture J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 820 - 829. [Abstract] [Full Text] [PDF] |
||||